echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The application for registration of new anticancer drug of Haite Biotech has been accepted

    The application for registration of new anticancer drug of Haite Biotech has been accepted

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 17th, the application for marketing authorization of recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand ("CPT") for injection submitted by Wuhan Haite Biopharmaceutical Co.


    CPT is a new recombinant protein targeting anti-tumor drug developed by its joint-stock subsidiary Beijing Shadong Biotechnology Co.


    Phase III clinical trials have shown that CPT combined with TD regimen in the treatment of relapsed and refractory multiple myeloma can significantly improve the progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) of patients.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.